Table 2.

Symptom burden (PRO-CTCAE) by time since last checkpoint inhibitor dose

Frequency	% reporting
	Overall (n=90)	<24 months (n=37)		24 to <36 months (n=27)		36+months (n=26)		P value
	Frequently/ almost constantly	Occasionally	Frequently/almost constantly	Occasionally	Frequently/almost constantly	Occasionally	Frequently/almost Constantly
Aching muscles	12	22	3	22	22	12	15	0.11
Aching joints	17	24	14	22	19	12	19	0.74
Headache	6	11	8	19	7	19	0	0.56
Vision problems*	3	3	0	30	0	4	12	<0.01
Fever†	0	0	0	0	0	0	0	--

Severity	Severe/very severe	Moderate	Severe/ very severe	Moderate	Severe/ very severe	Moderate	Severe/ very severe
Aching muscles	10	28	0	20	15	29	14	0.50
Aching joints	4	37	0	26	0	33	13	0.35
Headache	7	41	6	29	7	33	8	0.98
Itchy skin‡	9	16	14	22	7	4	4	0.18
Numbness/tingling§	11	0	5	4	19	4	12	0.23

Interference with daily activities	Quite a bit/Very much	Somewhat	Quite a bit/very much	Somewhat	Quite a bit/very much	Somewhat	Quite a bit/very much
Aching muscles	6	11	0	20	5	14	14	0.54
Aching joints	9	16	5	26	0	7	27	0.10
Headache	2	12	0	14	7	8	0	0.89
Numbness/tingling	9	0	0	27	18	11	11	0.05

*Only frequency is available for vision problems in the PRO-CTCAE.

†Only frequency is available for fever in the PRO-CTCAE.

‡Only severity of itchy skin is included in the PRO-CTCAE.

§Only severity and interference of numbness/tingling is included in the PRO-CTCAE.

PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Event.